NovoCure Ltd — Director's Dealing 2022

Oct 7, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NovoCure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2022-10-06

Reporting Person: Leonard Frank X (President, CNS Cancers US)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-10-06	Ordinary Shares	S	6754	$84.37	Disposed	50380	Direct

Footnotes

F1: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard.